Apple compound tested as natural muscle booster for seniors

NCT ID NCT07562698

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 03, 2026 · Updated 2 times

Summary

This study tests whether a supplement made from apple pomace (a byproduct of juicing) can improve muscle strength and physical function in older adults with mild sarcopenia—age-related muscle loss. About 105 people aged 65–80 will take either a low or high dose of the supplement or a placebo daily for 12 weeks. The main goal is to see if handgrip strength improves, along with other measures like walking speed and quality of life.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

105 people

The number who actually took part.

Started

May 2026

Finished

Aug 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

65 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 65 to 80 years (inclusive) * Male or female * Community-dwelling outpatients * Able and willing to provide written informed consent * Able to comply with study procedures and attend scheduled visits * Able to walk independently (assistive devices permitted) and safely perform physical performance assessments * Stable medical condition and stable medication regimen for at least 4 weeks prior to screening * Mild sarcopenia defined as: * SARC-F score ≥4 or clinical suspicion of sarcopenia, and Low muscle strength defined as: Handgrip strength \<27 kg for men or \<16 kg for women, or Five-times chair stand test \>15 seconds or inability to complete without use of arms \- Eligible for body composition assessment using bioelectrical impedance analysis (BIA) Exclusion Criteria: * Severe sarcopenia or severe functional impairment precluding safe participation * Unstable or uncontrolled medical conditions that may interfere with participation or safety * Severe renal or hepatic disease, including: * eGFR \<30 mL/min/1.73 m² * Significant liver disease or markedly abnormal liver function tests * Uncontrolled endocrine or metabolic disorders * Active malignancy or ongoing cancer treatment * Use of medications affecting muscle mass or function, including: * Chronic systemic corticosteroids * Anabolic steroids or testosterone therapy * Other investigational muscle-modifying agents * Recent structured resistance training within the past 3 months * Use of muscle-targeted supplements (e.g., creatine, HMB) within the previous 4-8 weeks * Contraindications to BIA (e.g., pacemaker or implanted electronic device) * Acute illness within 4 weeks prior to screening * Cognitive impairment preventing informed consent or protocol compliance * Known allergy or intolerance to ursolic acid or study product components * Any condition that, in the opinion of the investigator, may compromise safety, compliance, or data integrity

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Sarcopenia are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Sarcopenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Liaquat University Hospitals

    Jāmshoro, 76090, Pakistan

More trials for these conditions

Other studies related to the condition(s) this trial covers.